Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew E Barton

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJagdev S Sidhu, Maria Luisa Sardu, Marcus A Björnsson, et al.
Scandinavian Journal of Medicine & Science in Sports|November 13, 2019
Total body skeletal muscle mass estimated by magnetic resonance imaging and creatine (methyl-d<sub>3</sub> ) dilution in athletesTessa E Morris-Paterson, Stephen A Stimpson, Ram R Miller, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 27, 2017
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's diseaseSarah L Marrinan, Tal Otiker, Lakshmi S Vasist, et al.
Critical Care (London, England)|August 2, 2016
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trialMarianne J Chapman, Adam M Deane, Stephanie L O'Connor, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRalph P Maguire, William Byrnes, Matthew E Barton, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|June 30, 2018
Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE StudyAdam M Deane, Francois Lamontagne, George E Dukes, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentJagdev S Sidhu, Maria Luisa Sardu, Marcus A Björnsson, et al.
Scandinavian Journal of Medicine & Science in Sports|November 13, 2019
Total body skeletal muscle mass estimated by magnetic resonance imaging and creatine (methyl-d<sub>3</sub> ) dilution in athletesTessa E Morris-Paterson, Stephen A Stimpson, Ram R Miller, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 27, 2017
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's diseaseSarah L Marrinan, Tal Otiker, Lakshmi S Vasist, et al.
Critical Care (London, England)|August 2, 2016
The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trialMarianne J Chapman, Adam M Deane, Stephanie L O'Connor, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRalph P Maguire, William Byrnes, Matthew E Barton, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|June 30, 2018
Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE StudyAdam M Deane, Francois Lamontagne, George E Dukes, et al.
Pageof 2